Archive | November, 2018

Hot Investor Mandate: Global Biotech with Europe HQ Seeks to Partner with Early-Stage Therapeutic Assets in Oncology, Rare Diseases, and CNS that Address High Unmet Medical Need

21 Nov

A global biotech headquartered in Europe with multiple R&D facilities across the USA and Western Europe has several marketed products in oncology, rare diseases, and neurosciences and has global commercial and development capabilities. The Company is actively seeking to expand its pipeline by working with early stage biotechs and academic groups. The Company is open to a variety of deal structures and seeks to construct deals that maximize the potential of the therapeutic program by leveraging the capabilities of all partners involved while meeting the needs of the entrepreneur/startup. The Company is also an anchor investor in a newly launched venture fund that will have an associated accelerator which will start / fund project focused companies to work in close partnership with their R&D team. This fund will add additional flexibility in the Company’s ability to work with the early stage biotech and academic communities.

The Company is focused on enhancing its pipeline with oncology, rare disease, and select neuroscience drug assets. The Company is interested in highly differentiated late stage pre-clinical and clinical stage therapeutic candidates with strong scientific rationale targeting indications with significant unmet medical need.

The Company has no strict requirements for companies or management teams and looks to work creatively and collaboratively on partnerships with early-stage companies. The Company is open to opportunities/companies on a global basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Firm Seeks New Investment Opportunities in Broad Life Sciences, with Strong Interests in Cardiovascular, Oncology, Neurology Indications

21 Nov

A venture capital firm with offices in the Bay Area and Western Europe manages over $230m investing in Life Sciences companies with a stage agnostic strategy. The initial investment size ranges from $0.5 million for seed stage companies to $5 million for later stages ventures, and reserves significant capital for follow on investments. The fund invests in Europe, US and Israel.

The firm is currently looking for new investment opportunities in therapeutics, medical devices, diagnostics and digital health with a focus on cardiovascular, oncology and neurology although they are opportunistic in other areas.

The firm seeks to invest in both private and public companies based in Europe, US and Israel.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Europe-Based VC Firm Invests in Early-Stage Technologies that Target Age-Related Disease and Damages Associated with Aging

21 Nov

A new venture capital firm with headquarters in Europe seeks to make 2-4 equity investments in the range from $1-5M (EUR) per year. The firm is actively seeking new investments globally, with a focus in USA and Europe.

The firm invests in technologies that can treat age-related disease and damages associated with aging, such as altered protein homeostasis, cellular senescence, stem cell exhaustion, etc. The firm will consider companies working in therapeutics, diagnostics, nutritional products and advanced therapy medicinal products (gene therapy, cell therapy, tissue engineering) as long as they are relevant to the firm’s mission in targeting the basic mechanisms contributing to age-related disease. However, medical devices are currently not an area of focus. In therapeutics, the firm looks mostly at pre-clinical technologies with a validated proof-of-concept. The firm will consider companies in their later stages but prefers working with early-stage companies to provide company building and strategic support.

The firm can work with all types of management teams. The firm places higher importance in the actual science or technology in development as well as solid IP position. The firm seeks to work closely with their portfolio companies and can assist with building and structuring a full management team. As the firm generally comes in as the first institutional investor, they prefer to lead rounds and take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Innovation Challenge Application Portal Open for RESI San Francisco 2019

15 Nov

By Claire Jeong, Senior Research Analyst, LSN

claire

After finishing off another successful RESI event in New York City just last week, the LSN team is excitedly preparing for RESI San Francisco during JPM week on Tuesday, January 8th, 2019, our largest event of the year! We are now accepting applications for the RESI SF 2019 Innovation Challenge through our online portal, and companies can also submit a completed PDF application and supplementary materials to RESI@lifesciencenation.com. Our deadline is Friday, December 7th, 2018.

As usual, we will select 30 finalists from a pool of over 100 applicants across the globe and provide these finalists with the opportunity to present a posterboard showcasing their technologies at our exhibition hall for the entire day. The Innovation Challenge is open to early-stage companies in all sectors, from therapeutics, medical devices, diagnostics, and digital health.

Since RESI Boston in September 2018, we have been working with many regional tech hubs to bring the earliest stage technologies in front of our global network of investors. We will be selecting several companies to participate in the West Coast Innovators’ Pitch Challenge, to pitch in front of a panel of investor judges.

Last week, we announced the Top 3 Winners of the RESI NYC 2018 Innovation Challenge and showcased a wide range of innovative technologies (complete list can be found here). We look forward to receiving your applications for RESI SF 2019!

 

RESI San Francisco Panel Agenda

15 Nov

By Lucy Parkinson, VP of Investor Research, LSN

At LSN, we’re looking forward to a RESI San Francisco packed with meetings, content and new connections. Over a thousand attendees will join us for the event, and hundreds of investors are already registered to attend. In addition to the networking potential of RESI San Francisco, LSN has also created an agenda full of investor panels related to key technologies and sources of investment in the early stage life science arena. These panels aim to inform entrepreneurs on who’s out there writing checks, and how to get on their radar.

RESI San Francisco will feature an Asia Track in the afternoon, including a new panel on Asia Corporates & Strategics, and our first ever devoted panel on Taiwan Investors, led by BioMed Taiwan. The event also includes RESI’s first ever panel devoted to Investing in Cell & Gene Therapy, a West Coast Innovator’s Pitch Challenge, and the return of RESI’s popular sessions on Mental & Behavioural Health, Corporate Venture Capital, and Personalized Medicine. If you’d like to join us for this full day of content, register now!

Announcing the Digital Health Panel for RESI San Francisco 2019

15 Nov

By Karen Deyo, Investor Research Analyst, LSN

The Digital Health sector has been rapidly expanding, with applications ranging from consumer-facing technologies to physician tools for care coordination to AI-based diagnostics platforms. The nature of this sector, with the much shorter time-to-commercialization as well as the ease in entering the market has led to a great deal of investment in this space. However, this leads to some big differences in the strategies employed by investors, as well as unique challenges faced by fundraising CEOs in this space. In addition, companies and investors alike must take into account the shifting regulatory environment as the FDA grapples with a strategy to evaluate Digital Health technologies, either as standalone products or as part of combination devices.

At our upcoming RESI conference in San Francisco on January 8th, we have five investors who focus on Digital Health who are willing to share their expertise about what’s hot, what not to do and how to face the challenges and avoid the pitfalls that are common in this sector. Make sure to make your way to the panel, taking place from 10:00-10:50 am!

The panelists speaking on the Digital Health panel are:

  • Dennis Depenbusch, Director, New Ventures Initiative, BCBSKS New Ventures Initiative
  • Brenda Irwin, Managing Partner & Co-Founder, Relentless Pursuit Partners
  • Dominik Mayer, Principal, AO Invest
  • Skip Fleshman, Partner, Asset Management Ventures
  • Debbie Lin, Executive Director – Digital Health, Boehringer Ingelheim Venture Fund

Hot Investor Mandate: Life Sciences Investment Firm with Over $1B+ AUM Invests in Therapeutics, Devices, Diagnostics, Digital Health, and Drug Discovery & Research Tools

15 Nov

A life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, is actively involved in innovation, restructuring opportunities, and growth investing. The firm’s investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of the firm’s partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members. The firm has no set number of allocations that it plans to make but is actively reviewing new opportunities from around the globe. The firm has a history of strategic relationships with other venture capital firms or funds targeting specific sectors or geographies within the life sciences. These working relationships help give them a global footprint and vastly expand the firm’s deal flow.

The firm’s general life sciences funds represent approximately $1.3 billion in capital commitments. These funds target a diverse group of life sciences companies, across all stages of development. Bay City Capital funds have invested in a total of 100 portfolio companies covering a broad range of life science sectors, including biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, digital health, nutrition, and agribusiness.

The firm seeks to invest its capital in life sciences companies where their operational, financial, and scientific expertise can assist management in building companies. This investment approach has remained largely consistent since 1997, delivering attractive returns to their investors. Effective management is critical to the success of their portfolio companies. The firm assists their portfolio companies in recruiting and retaining key management and advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with product development and execution. The firm develops close working relationships with their management teams to establish themselves as true partners in business building.

The firm strongly prefers board representation, and have received a board seat with 90% of their portfolio companies (based on invested capital). The firm believes this commitment of intellectual capital increases the likelihood of positive outcomes for their investments, and has established them as a preferred partner in the industry.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →